Prostate Cancer News
Following Lifestyle Recommendations Reduces Risk of Cancer Death (May 15, 2013)People who follow the diet and lifestyle recommendations laid out by the World Cancer Research Fund (WCRF) and the American Institute for Cancer Research (AICR) have a 34 percent reduced risk of dying from several diseases and specifically, a 20 percent... Continue Reading
Genomic Test May Help Guide Prostate Cancer Treatment (May 13, 2013)A new genetic test—the Oncotype DX® Prostate Cancer Test—measures the aggressiveness of prostate cancer and may help scores of men choose between immediate treatment or active surveillance. The test was shown to strongly predict aggressiveness of... Continue Reading
Early Radiation Improves Prostate Cancer Survival (March 7, 2013)Immediate radiation therapy after radical prostatectomy resulted in a 50 percent increase in long-term biochemical progression-free survival (bNED) in men with locally advanced prostate cancer, according to the results of a study presented at the Genitourinary... Continue Reading
Surgery and Radiation for Prostate Cancer Produce Similar Functional Outcomes (February 27, 2013)Men with localized prostate cancer experience declines in sexual, urinary, and bowel function over time, regardless of whether they choose surgery or radiation therapy, according to the results of a study published in the New England Journal of Medicine. Each... Continue Reading
Cancer Deaths on the Decline (February 11, 2013)Overall cancer death rates continue to decline in both men and women and across major ethnic and racial groups, according to the annual Status of Cancer report published in the Journal of the National Cancer Institute. What’s more—cancer incidence... Continue Reading
No Difference in Toxicity Between Proton Therapy and IMRT for Prostate Cancer (January 28, 2013)Proton therapy does not reduce toxicity compared with intensity-modulated radiation therapy (IMRT) in men with prostate cancer, according to the results of a study published in the Journal of the National Cancer Institute. Prostate cancer is the most... Continue Reading
Prostate Cancer Screening Can Take a Toll on Quality of Life (December 19, 2012)Screening for prostate cancer carries some risks and can affect quality of life. Considering these risks is important when making the decision about whether to be screened. The results of a study that assessed both the potential benefits of screening... Continue Reading
Zytiga Approval Expanded (December 17, 2012)The U.S. Food and Drug Administration (FDA) has expanded the approved use of Zytiga® (abiraterone) to treat men with metastatic, hormone-refractory prostate cancer prior to receiving chemotherapy. Prostate cancer is a hormonally sensitive disease that... Continue Reading
Viagra Improves Sexual Function after Radiation for Prostate Cancer (November 15, 2012)Viagra® (sildenafil citrate) administered before, during, and after radiation therapy improved overall sexual function in prostate cancer patients, according to the results of a study presented at the 54th annual meeting of the American Society for... Continue Reading
Intermittent and Continuous Hormone Therapy are Equally Effective in Prostate Cancer Treatment (September 18, 2012)Hormone therapy given intermittently (with breaks) has proven to be as effective as hormone therapy given continuously in asymptomatic men with rising PSA levels after prostate cancer treatment, according to the results of a study published in the New... Continue Reading
Latest Prostate Cancer News By Stage
Early Stage I-II (A-B) Prostate Cancer
Genomic Test May Help Guide Prostate Cancer Treatment (May 13, 2013)
A new genetic test—the Oncotype DX® Prostate Cancer Test—measures the aggressiveness of prostate cancer and may help scores of men choose between immediate treatment or active surveillance. The test was shown to strongly predict aggressiveness of... Continue Reading
Surgery and Radiation for Prostate Cancer Produce Similar Functional Outcomes (February 27, 2013)Men with localized prostate cancer experience declines in sexual, urinary, and bowel function over time, regardless of whether they choose surgery or radiation therapy, according to the results of a study published in the New England Journal of Medicine. Each... Continue Reading
No Difference in Toxicity Between Proton Therapy and IMRT for Prostate Cancer (January 28, 2013)Proton therapy does not reduce toxicity compared with intensity-modulated radiation therapy (IMRT) in men with prostate cancer, according to the results of a study published in the Journal of the National Cancer Institute. Prostate cancer is the most... Continue Reading
Viagra Improves Sexual Function after Radiation for Prostate Cancer (November 15, 2012)Viagra® (sildenafil citrate) administered before, during, and after radiation therapy improved overall sexual function in prostate cancer patients, according to the results of a study presented at the 54th annual meeting of the American Society for... Continue Reading
Intermittent and Continuous Hormone Therapy are Equally Effective in Prostate Cancer Treatment (September 18, 2012)Hormone therapy given intermittently (with breaks) has proven to be as effective as hormone therapy given continuously in asymptomatic men with rising PSA levels after prostate cancer treatment, according to the results of a study published in the New... Continue Reading
More Early Stage I-II (A-B) Prostate CancerLocally Advanced Stage III (C) Prostate Cancer
Genomic Test May Help Guide Prostate Cancer Treatment (May 13, 2013)
A new genetic test—the Oncotype DX® Prostate Cancer Test—measures the aggressiveness of prostate cancer and may help scores of men choose between immediate treatment or active surveillance. The test was shown to strongly predict aggressiveness of... Continue Reading
Early Radiation Improves Prostate Cancer Survival (March 7, 2013)Immediate radiation therapy after radical prostatectomy resulted in a 50 percent increase in long-term biochemical progression-free survival (bNED) in men with locally advanced prostate cancer, according to the results of a study presented at the Genitourinary... Continue Reading
No Difference in Toxicity Between Proton Therapy and IMRT for Prostate Cancer (January 28, 2013)Proton therapy does not reduce toxicity compared with intensity-modulated radiation therapy (IMRT) in men with prostate cancer, according to the results of a study published in the Journal of the National Cancer Institute. Prostate cancer is the most... Continue Reading
Viagra Improves Sexual Function after Radiation for Prostate Cancer (November 15, 2012)Viagra® (sildenafil citrate) administered before, during, and after radiation therapy improved overall sexual function in prostate cancer patients, according to the results of a study presented at the 54th annual meeting of the American Society for... Continue Reading
Intermittent and Continuous Hormone Therapy are Equally Effective in Prostate Cancer Treatment (September 18, 2012)Hormone therapy given intermittently (with breaks) has proven to be as effective as hormone therapy given continuously in asymptomatic men with rising PSA levels after prostate cancer treatment, according to the results of a study published in the New... Continue Reading
More Locally Advanced Stage III (C) Prostate CancerMetastatic Stage IV (D) Prostate Cancer
Genomic Test May Help Guide Prostate Cancer Treatment (May 13, 2013)
A new genetic test—the Oncotype DX® Prostate Cancer Test—measures the aggressiveness of prostate cancer and may help scores of men choose between immediate treatment or active surveillance. The test was shown to strongly predict aggressiveness of... Continue Reading
No Difference in Toxicity Between Proton Therapy and IMRT for Prostate Cancer (January 28, 2013)Proton therapy does not reduce toxicity compared with intensity-modulated radiation therapy (IMRT) in men with prostate cancer, according to the results of a study published in the Journal of the National Cancer Institute. Prostate cancer is the most... Continue Reading
Zytiga Approval Expanded (December 17, 2012)The U.S. Food and Drug Administration (FDA) has expanded the approved use of Zytiga® (abiraterone) to treat men with metastatic, hormone-refractory prostate cancer prior to receiving chemotherapy. Prostate cancer is a hormonally sensitive disease that... Continue Reading
Intermittent and Continuous Hormone Therapy are Equally Effective in Prostate Cancer Treatment (September 18, 2012)Hormone therapy given intermittently (with breaks) has proven to be as effective as hormone therapy given continuously in asymptomatic men with rising PSA levels after prostate cancer treatment, according to the results of a study published in the New... Continue Reading
Xtandi Approved for Metastatic Hormone-Refractory Prostate Cancer (September 13, 2012)The U.S. Food and Drug Administration (FDA) has approved Xtandi® (enzalutamide) for the treatment of patients with metastatic, hormone-refractory prostate cancer who have previously received docetaxel. The prostate is a male sex gland responsible for... Continue Reading
More Metastatic Stage IV (D) Prostate CancerRefactory/Recurrent Prostate Cancer
Genomic Test May Help Guide Prostate Cancer Treatment (May 13, 2013)
A new genetic test—the Oncotype DX® Prostate Cancer Test—measures the aggressiveness of prostate cancer and may help scores of men choose between immediate treatment or active surveillance. The test was shown to strongly predict aggressiveness of... Continue Reading
No Difference in Toxicity Between Proton Therapy and IMRT for Prostate Cancer (January 28, 2013)Proton therapy does not reduce toxicity compared with intensity-modulated radiation therapy (IMRT) in men with prostate cancer, according to the results of a study published in the Journal of the National Cancer Institute. Prostate cancer is the most... Continue Reading
Intermittent and Continuous Hormone Therapy are Equally Effective in Prostate Cancer Treatment (September 18, 2012)Hormone therapy given intermittently (with breaks) has proven to be as effective as hormone therapy given continuously in asymptomatic men with rising PSA levels after prostate cancer treatment, according to the results of a study published in the New... Continue Reading
Xtandi Approved for Metastatic Hormone-Refractory Prostate Cancer (September 13, 2012)The U.S. Food and Drug Administration (FDA) has approved Xtandi® (enzalutamide) for the treatment of patients with metastatic, hormone-refractory prostate cancer who have previously received docetaxel. The prostate is a male sex gland responsible for... Continue Reading
Enzalutamide Prolongs Survival in Metastatic Prostate Cancer (August 27, 2012)Enzalutamide, an experimental androgen receptor antagonist drug, significantly prolongs survival in men with metastatic hormone-refractory prostate cancer after chemotherapy, according to the results of a study published in the New England Journal... Continue Reading
More Refactory/Recurrent Prostate CancerScreening/Prevention Prostate Cancer
Prostate Cancer Screening Can Take a Toll on Quality of Life (December 19, 2012)
Screening for prostate cancer carries some risks and can affect quality of life. Considering these risks is important when making the decision about whether to be screened. The results of a study that assessed both the potential benefits of screening... Continue Reading
Aspirin and Cancer Risk and Mortality (September 17, 2012)Aspirin and cancer risk is in the news again—and the link is still unclear. Two studies published early online in the Journal of Clinical Oncology evaluated the relationship between aspirin and cancer risk—one indicated that aspirin does not appear... Continue Reading
New Screening Method May Help Diagnose Undetectable Prostate Cancer (August 16, 2012)Men with persistently increased or fluctuating prostate specific antigen (PSA) levels and a negative prostate biopsy may benefit from a new prostate cancer screening method that uses the combination of a novel drug therapy plus changes in PSA levels over... Continue Reading
PSA Testing May Be Appropriate for Some Men (July 25, 2012)The American Society of Clinical Oncology (ASCO) has released a Provisional Clinical Opinion (PCO) suggesting that that men with a longer life expectancy—those with at least 10 more years to live—discuss with their physician the potential risks and... Continue Reading
Side Effects of Prostate Cancer Treatment Persist Long-Term (July 5, 2012)Men who are treated for prostate cancer may continue to suffer from side effects 10 years after treatment, according to the results of a study published in the Journal of Clinical Oncology. Each year in the United States, more than 192,000 men are diagnosed... Continue Reading
More Screening/Prevention Prostate Cancer